Baseline characteristics of patients
| Characteristic | All patients (n= 7757) | Insulin-naive patients (n= 1159) |
|---|---|---|
| Sex, n (%) | ||
| Male | 4268 (55.0) | 647 (55.8) |
| Female | 3489 (45.0) | 512 (44.2) |
| Age, years, mean (SD) | 67.4 (11.0) | 65.8 (12.0) |
| Age, in categories, n (%) | ||
| 40–55 years | 1221 (15.7) | 258 (22.3) |
| 56–70 years | 3324 (42.9) | 464 (40.0) |
| 71–85 years | 2859 (36.9) | 376 (32.4) |
| ≥86 years | 353 (4.6) | 61 (5.3) |
| Number of chronic diseases, mean (SD) | 3.7 (1.8) | 3.5 (1.8) |
| Chronic diseases, in categories | ||
| 0–1 diseases | 665 (8.6) | 127 (11.0) |
| 2–4 diseases | 4882 (62.9) | 746 (64.4) |
| ≥5 diseases | 2210 (28.5) | 286 (24.7) |
| Duration of T2DM, years, mean (SD) | 13.1 (6.1) | 9.9 (5.9) |
| Duration of T2DM, in categories | ||
| 0–5 years | 708 (9.1) | 256 (22.1) |
| 6–10 years | 1624 (20.9) | 309 (26.7) |
| 11–15 years | 2217 (28.6) | 308 (26.6) |
| 16–20 years | 1465 (18.9) | 129 (11.1) |
| ≥21 years | 790 (10.2) | 41 (3.5) |
| Unknown | 953 (12.3) | 116 (10.0) |
| Number of blood glucose lowering drugs, mean (SD) | 1.5 (0.62) | 1.9 (0.73) |
| Drug | ||
| Metformin | 7098 (91.5) | 1033 (89.1) |
| Sulfonylurea | 3502 (45.1) | 863 (74.5) |
| Dipeptidyl peptidase-4 inhibitors | 286 (3.7) | 167 (14.4) |
| Glucagon-like peptide-1 agonists | 399 (5.1) | 74 (6.4) |
| Sodium-glucose co-transporter-2 inhibitors | 306 (3.9) | 63 (5.4) |
| Acarbose | 15 (0.2) | 2 (0.2) |
| Meglitinides | 13 (0.2) | 1 (0.1) |
| Thiazolidinediones | 31 (0.4) | 8 (0.7) |
SD = standard deviation. T2DM = type 2 diabetes mellitus.